CLX was the first COX-2 inhibitor approved by the FDA (U.S Food and Drug Administration) for the treatment of OA and rheumatoid arthritis, due to its good selectivity for the COX-2 enzyme and for its gastrointestinal tolerability [13]. The gene discussed is PTGS2; the disease is rheumatoid arthritis.